Drug intelligence / Profile preview

BLS-H03

Development stage: Preclinical
Lead developer: MOA Life Plus
Modality: Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Intramuscular, Subcutaneous

Overview

BLS-H03 is a vaccine adjuvant candidate being developed by MOA Life Plus (formerly BioLeaders) based on the company's proprietary HumaMAX platform. The HumaMAX platform utilizes high-molecular-weight poly-gamma-glutamic acid (γ-PGA), a biodegradable and non-toxic polymer produced by *Bacillus subtilis*. BLS-H03 is designed to function as an immunostimulant that enhances the efficacy of vaccines by promoting the maturation of dendritic cells and inducing the production of Th1-type cytokines, primarily through the activation of Toll-like receptor 4 (TLR4). It is currently in the preclinical research and efficacy testing phase, aimed at improving the immune response to various vaccine antigens.

Other names: HumaMAX vaccine adjuvantpoly-gamma-glutamic acid adjuvant

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on BLS-H03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLS-H03.

Explore the full profile